NAOV - NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract

• NanoVibronix ( NASDAQ: NAOV ) said on Friday its UroShield had been approved to be sold in the UK by the NHS Supply Chain through a new contract.
• ( NAOV ) has risen ~27% before the bell.
• NHS Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organizations across England and Wales.
• The new contract will begin in October and will merge with the existing Urology and Stoma framework contract in February 2024 with optional extension periods.
• UroShield is a disposable ultrasound device designed to reduce the risk of catheter-associated urinary tract infection (CAUTI) by reducing bacterial colonization and biofilm formation on indwelling urinary catheters.

For further details see: